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The behaviour of the C-reactive protein as a
measure of rheumatic activity has been the subject
of several publications. Most investigators have
studied the C-reactive protein test in cases of frank
rheumatic fever in children and there have been only
isolated observations on its value in the assessment
of rheumatic activity in chronic rheumatic heart
disease in adults. Elster, Braunwald, and Wood
(1956) suggested that the test might be helpful in
the detection of subclinical rheumatic activity in
such patients. Although recurrences of rheumatic
fever become less frequent with advancing age, it is
possible that rheumatic activity of this kind is more
common in adults than is generally appreciated
(Roberts, 1954; Biorck, 1955; Mortimer and
Rammelkamp, 1956). Recently, Roberts (1954)
stressed again that the course of rheumatic heart
disease can be most appropriately described as
polycyclic, phases of activity alternating with
periods of apparent clinical quiescence. With this
idea in mind, we have studied a group of unselected
patients with rheumatic fever and rheumatic heart
disease and have attempted to determine the value
and limitations of the C-reactive protein test as a
measure of rheumatic activity at various stages of
the disease process.
Material and Method
The 215 patients studied were divided into four groups
according to the clinical picture:
(A) Twelve patients with active rheumatic carditis
satisfying the criteria of Jones (1944); six of these were
experiencing their first attack of carditis and the other six
already had established valvular lesion.
(B) 61 patients with chronic rheumatic heart disease
in whom the presence of rheumatic activity could not be
established on clinical grounds. These patients were
grouped together because they all showed signs of
progressive deterioration and had either experienced
cardiac failure before this study was undertaken, or
were suffering from it while the study was being carried
out.
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(C) 134 Patients with chronic rheumatic heart disease
who were considered clinically to be in a quiescent stage.
These patients had never had cardiac failure and the
size of the heart had remained unchanged for several
years.
(D) Eight patients with chorea and no other rheumatic
manifestation.
426 C-reactive protein tests were carried out on these
215 patients according to the method of Anderson and
McCarty (1950), using commercial C-reactive protein
antiserum-Schieffelin. Other tests, including the erythro-
cyte sedimentation rate, were carried out at the same
time. The laboratory aspects and the comparative value
of these tests are the subject of a separate communication
(Eastham, Szekely, and Davison (1958).
Results
The behaviour of the C-reactive protein in the
four clinical groups is shown in the Table.
Group A.-All patients with clear evidence of
active rheumatic carditis gave a positive test for
C-reactive protein.
TABLE I
C-REACTIVE PROTEIN IN RHEUMATIC FEVER AND
RHEUMATIC HEART DISEASE
C-Reactive Protein
Clinical Group No. of Average
Patients Age (yrs) Present Absent















activity 134 32 11 123
No cardiac
failure
(D) Chorea only 8 12 0 8
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Six of these patients were treated with prednisone
for 10 to 73 days. Clinical improvement was rapid
and the C-reactive protein disappeared from the
serum in all six patients between 6 and 18 days after
the start of the treatment. In four patients, the
abnormal protein reappeared between 8 and 14 days
after discontinuation of prednisone: in three of these
the test became negative again within a fortnight
without further treatment, but in the fourth patient
it remained positive and she had a clinical relapse
within a month.
The behaviour of the C-reactive protein in a
patient treated with prednisone is illustrated in the
Figure.
Six patients were treated with salicylates only and
here the C-reactive protein persisted for 4 to 6 weeks.
Group B.-C-reactive protein was present in 47
of the 61 patients with chronic rheumatic heart
disease whose cardiac condition was judged to be
progressive but in whom no certain clinical criteria
of rheumatic activity could be found. Of the 47
patients, 25 were experiencing cardiac failure,
associated with bronchitis in four and embolic
episodes in five, at the time of the initial laboratory
investigation. Two further patients had embolic
episodes without cardiac failure.
In seven patients the C-reactive protein test
became negative after the signs of cardiac failure had
disappeared, but in seven others it persisted in spite
of comparable clinical improvement.
In the remaining eleven patients with cardiac














In the two patients who had embolic episodes
without cardiac failure, there was a reversal from
the initial positive test to a negative within a week.
Of the fourteen patients in this group with a
negative C-reactive protein test five were suffering
from cardiac failure; none of these had respiratory
infection or embolic episodes.
Group C.-Of the 134 patients with chronic
rheumatic heart disease who were considered
clinically to be in a quiescent stage, eleven had a
positive C-reactive protein test. Two of these had
bronchitis and one had a pulmonary infarct. A
fourth patient had arthralgia and 6 months later
developed rheumatoid arthritis. In two patients
there had been a recent change from sinus rhythm
to atrial fibrillation. The remaining five patients
were in every way comparable to the large number
of patients in this group in whom C-reactive protein
was absent.
Group D.-In the eight patients who had chorea
and no other rheumatic manifestations, the C-reac-
tive protein test was invariably negative.
C-Reactive Protein and Aschof Bodies
There were seven patients in whom auricular
biopsies were available for examination after mitral
valvotomy who also had pre-operative C-reactive
protein determinations. Five had a positive test
and in four of these Aschoff bodies were demon-
strated. Aschoff bodies were also found in two
patients with negative C-reactive protein tests.
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Two further patients came to autopsy: one had a
negative C-reactive protein test in the presence of
many Aschoff bodies in the left atrium and left
ventricle, and in the other the C-reactive protein test
was positive and no Aschoff bodies were found in
the heart muscle.
Discussion
Anderson and McCarty (1950) stated that the
detection of C-reactive protein in the serum was the
most consistently positive laboratory finding in the
presence of rheumatic activity. A similar opinion
was later expressed by Bunim, Kuttner, Baldwin,
and McEwen (1952) and Stollerman, Glick, Patel,
Hirschfield, and Rusoff (1953). Hill (1952) also
stated that the C-reactive protein faithfully reflected
the fluctuations in the activity of the disease.
However, this protein has not been invariably
present in active rheumatic disease (Shackman,
Heffer, and Kroop, 1954). In the present series
C-reactive protein could be detected in every case
where the clinical findings indicated an active
rheumatic process.
Treatment with prednisone led to disappearance
of the C-reactive protein within 3 weeks and there
was a parallel clinical improvement in all patients
so treated. Similar results have been obtained by
others (Bunim and others, 1952; Stollerman, Glick,
and Anderson, 1954; McEwen, 1955; Bunim, 1956;
Rahman and Mozziconacci, 1957). However, opin-
ions have differed whether this indicates complete
suppression of rheumatic activity or not. Accord-
ing to McEwen and Ziff (1955), the C-reactive
protein test is not a reliable guide to rheumatic
activity during hormone treatment because of the
direct effect of the hormones on this protein. On
the other hand, there is evidence to show that the
disappearance of C-reactive protein from the serum
during treatment with adreno-cortical hormones or
with salicylates is due to suppression of the inflam-
matory process rather than to a primary effect of
these agents upon the metabolism of C-reactive
protein (Stollerman and others, 1954; Hedlund,
Frisk, and Bucht, 1956). Stollerman and others
(1953) also emphasize that the persistence of
C-reactive protein during treatment indicates in-
complete suppression of the inflammatory process
and that treatment should be continued until the
positive reaction becomes negative. Yocum and
Doerner (1957) also found that large doses of
hormones in rheumatic fever did not cause the
C-reactive protein to disappear as long as rheumatic
activity was clinically evident. Rahman and
Mozziconacci (1957) found that the C-reactive
protein persisted longer in patients treated with
salicylates than in the hormone-treated group, and
this is in keeping with our own observations.
The C-reactive protein was found to reappear in
the serum after discontinuation of hormone therapy
(Ziegra and Kuttner, 1951; Stollerman and others,
1953; Shackman and others, 1954). Bunim (1956)
reported that, when hormonal administration was
discontinued, the C-reactive protein temporarily
reappeared in 40 per cent. of cases. Rahman and
Mozziconacci (1957) found a reversal of the C-
reactive protein test from negative to positive in
27 per cent. of the cases. We also found that
C-reactive protein reappeared after discontinuing
prednisone in four cases. Dawson (1957) stated
that, in those cases which relapsed, the C-reactive
protein test became positive a few days before the
relapse became clinically apparent. Shackman and
others (1954) expressed the opinion that only
continued observation for at least 3 weeks, without
re-institution of therapy, can differentiate between a
rebound and persisting rheumatic activity.
When chorea was the only rheumatic manifesta-
tion, the C-reactive protein was invariably absent.
This is in keeping with the findings of previous
investigators (Anderson and McCarty, 1950; Stoller-
man and others, 1953; Wood and McCarty, 1954;
Dawson, 1957; Rahman and Mozziconacci, 1957).
Shackman and others (1954) reported two patients
with chorea who had a positive C-reactive protein
test but both had concurrent carditis. These
authors stressed that a positive test in chorea should
suggest an associated carditis and that a negative
test is presumptive evidence of its absence.
The present observations suggest that single
C-reactive protein determinations in chronic rheum-
atic heart disease in the absence of clinical evidence
of rheumatic activity may be misleading, but that
repeated tests interpreted in conjunction with the
clinical progress may be helpful in the assessment
and management of these cases. Those patients in
whom the disease progressed very little, if at all, over
a period of years, as judged by the lack of symptoms,
absence of progressive cardiac enlargement, and
cardiac failure, showed as a rule repeatedly negative
C-reactive protein tests. Shackman and others
(1954) also stated that a negative C-reactive protein
test was an accurate measure of the inactive state.
A clinical analysis of the cases included in Group B
showed that the 47 patients who had an initial or
persistent positive C-reactive protein test represented
a more advanced condition within the group, as
judged by exercise tolerance and cardiac size, than
the fourteen patients without C-reactive protein. In
view of the non-specific nature of the C-reactive
protein test, we do not feel justified in concluding
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how many, if any, of these patients had in fact active
rheumatic carditis. However, it would appear from
the present study that a persistently positive C-
reactive protein test in chronic rheumatic heart
disease is a significant finding because it is more
often than not associated with progressive cardiac
enlargement and clinical deterioration.
Although C-reactive protein is usually present in
congestive cardiac failure with rheumatic activity
(Bywaters, 1956), the findings of Elster and others
(1956) tend to show that congestive heart failure
per se may give rise to a positive test. On the other
hand, Stollerman and others (1953) and McEwen
and Ziff (1955) believe that congestive cardiac
failure is not responsible for the appearance of this
protein. In the present series, C-reactive protein
disappeared from the serum in several patients after
the signs of cardiac failure had cleared up; in other
patients it persisted in spite of comparable clinical
improvement, and yet in other cases it was not
present at all during the stage of cardiac failure.
These findings suggest that congestive cardiac
failure per se is not likely to be responsible for the
production of C-reactive protein. Embolic episodes
or respiratory infection are known to account for a
positive test (Hedlund, 1947; Roantree and Rantz,
1955; Elster and others, 1956; Yocum and Doerner,
1957), and these complications were present in some
of our patients.
Several patients with a positive C-reactive protein
test were pregnant, but in our experience pregnancy
does not influence the behaviour of this protein.
In 48 normal pregant women at various stages of
their pregnancy, the test was invariably negative.
This is in agreement with the findings of Hedlund
(1947) and Shetlar, Bullock, Shetlar, and Payne
(1955).
Elster and Wood (1955) reported on the lack of
correlation between pre-operative C-reactive protein
tests and the presence of Aschoff bodies in auricular
biopsies obtained from patients undergoing mitral
valve surgery. We have also encountered instances
of negative C-reactive protein tests in the presence
of Aschoff bodies. Elster and Wood (1955) suggest
that, in these cases, the pathological process is not
sufficiently active to lead to the production of
C-reactive protein, and that the degree of rheumatic
activity may have little or no clinical significance.
Summary
The behaviour of C-reactive protein was studied
in patients with rheumatic fever and rheumatic
heart disease at various stages of the disease process.
C-reactive protein was always present in active
rheumatic carditis and proved a useful guide in the
management of these cases.
In cases of isolated chorea, C-reactive protein was
invariably absent and this appeared to be good
evidence of the absence of concurrent carditis.
The value and limitations of the test in chronic
heart disease in the absence of obvious clinical
evidence of rheumatic activity are discussed.
Our thanks are due to Dr. W. G. A. Swan and Dr. F.
Jackson for their help and criticism. We should also
like to thank Dr. G. Davison, Dr. G. Richardson, and
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patients. The mitral valve operations referred to in the
paper were performed by Mr. G. A. Mason. We are
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Proteine C-reactive dans la maladie de Bouillaud
RfsuMt
On etudia le comportement de la proteine C-reactive
chez des malades atteints de maladie de Bouillaud a de
differentes periodes evolutives.
La proteine C-reactive fut toujours presente dans la
cardite rhumatismale active et se revela utile dans le
maniement de ces cas.
Dans des cas de choree seule, la proteine C-reactive
fut invariablement absente, fournissant ainsi une preuve
d'absence d'une cardite concomitante.
On discute la valeur et les limitations de cette epreuve
dans la maladie rhumatismale chronique du coeur en
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l'absence de preuves cliniques apparentes d'activite en la presencia de carditis reumatica activa y se revel6
rhumatismale. uitil en el manejo de estos casos.
En casos de corea sola, la ausencia invariable de la
Proteina C-reactiva en la enfermedad de Bouillaud proteina C-reactiva ofrecia una prueba vAlida de ausencia
SUMARIO de una carditis concomitant.
Se estudi6 el comportamiento de la proteina C-reactiva Se discute el valor y las limitaciones de esta reacci6n
en los pacientes con la enfermedad de Bouillaud en en la enfermedad reumatica cronica del corazon en la
diferentes periodos evolutivos. ausencia de pruebas clinicas aparentes de actividad
La proteina C-reactiva se pudo siempre demostrar reumAtica.
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